Emergency Task Force (ETF) recommendations
Submitted by Anonymous (not verified) on 29 May 2026 - 12:39
Emergency Task Force (ETF) recommendations
ETF recommends updating COVID-19 vaccines to target XFG variant
Submitted by Anonymous (not verified) on 29 May 2026 - 12:35
ETF recommends updating COVID-19 vaccines to target XFG variant
EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027
Submitted by Anonymous (not verified) on 29 May 2026 - 12:34
EMA recommendation to update the antigenic composition of authorised COVID-19 vaccines for 2026-2027
Need for maximum residue limit (MRL) evaluation for biological substances - Scientific guideline
Submitted by Anonymous (not verified) on 29 May 2026 - 12:00
Need for maximum residue limit (MRL) evaluation for biological substances - Scientific guideline
List of centrally authorised products with safety-related changes to the product information
Submitted by Anonymous (not verified) on 29 May 2026 - 11:45
List of centrally authorised products with safety-related changes to the product information
Scientific advice for high-risk medical devices
Submitted by Anonymous (not verified) on 29 May 2026 - 10:17
Scientific advice for high-risk medical devices
Concept paper on the need for revision of the guideline on the development of medicinal products for the treatment of smoking
Submitted by Anonymous (not verified) on 29 May 2026 - 9:34
Concept paper on the need for revision of the guideline on the development of medicinal products for the treatment of smoking
Quality of medicines: questions and answers - Part 2
Submitted by Anonymous (not verified) on 29 May 2026 - 8:56
Quality of medicines: questions and answers - Part 2
Human medicines European public assessment report (EPAR): Adtralza, tralokinumab, Date of authorisation: 17/06/2021, Revision: 10, Status: Authorised
Submitted by Anonymous (not verified) on 28 May 2026 - 16:32
Human medicines European public assessment report (EPAR): Adtralza, tralokinumab, Date of authorisation: 17/06/2021, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Pomalidomide Teva, pomalidomide, Date of authorisation: 14/11/2024, Revision: 2, Status: Authorised
Submitted by Anonymous (not verified) on 28 May 2026 - 16:30
Human medicines European public assessment report (EPAR): Pomalidomide Teva, pomalidomide, Date of authorisation: 14/11/2024, Revision: 2, Status: Authorised